Arovella Newsletter April 2024
Welcome everyone to another instalment containing the latest updates at Arovella. We have had a busy start to the year, and we are delighted with our progress, and how the company is positioned for the months and years ahead.
Let me first start by saying thank you to all our shareholders for their continued support in the company. In March, we were delighted to complete a $12.5m Placement, which enabled us to add global, institutional-grade investors to the shareholder register. It is wonderful to have their support at a critical juncture for the company. This is particularly exciting as Arovella is now funded to take our lead product, ALA-101, into a phase 1 clinical trial and to collect preliminary data from this trial. We look forward to providing updates as this important work progresses.
Highlights:
Completed $12.5m placement ensuring the company is funded to Phase 1 data
Secured global license with UNC for novel armouring cytokine technology IL-12-TM to enhance Arovella’s CAR-iNKT platform
Released and received Good Manufacturing Practice (GMP) grade lentiviral vector for our lead product, ALA-101
Presented at the annual AACR conference in San Diego, USA
Strengthened our Scientific Advisory Board with the appointment of Professor Gianpietro Dotti
Dr Michael Baker
CEO and MD
